TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01854359

Intervention type: DRUG
Group type: OTHER
Intervention: Idebenone
Study: NCT01787461

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Imedeen
Description: Two tablets per day for 6 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets per day for 6 months
Study: NCT00311766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin Beta 4
Description: Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Study: NCT01871701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00311766

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
Study: NCT03073421

Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative interview
Description: This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
Study: NCT02536898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fracture Liaison Service

Intervention type: OTHER
Group type: OTHER
Intervention: Current treatment
Study: NCT03678701

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-meal 100% whey protein intake
Description: Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
Study: NCT04868955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral screen training
Description: Oral screen training (IQoro®) during 13 weeks.
Study: NCT01611038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylselenocysteine
Description: Methylselenocysteine capsule given daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule given daily
Study: NCT01687608

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AskBio009
Description: Single dose IV injection
Study: NCT03568240

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients suffering from Sleep apnea
Description: PSG test

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients suffering from Sleep apnea
Description: PSG test

Intervention type: DIAGNOSTIC_TEST
Intervention: Patients suffering from Sleep apnea
Description: PSG test
Study: NCT01154868

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Alveolar ridge augmentation
Description: Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
Study: NCT03965013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: 2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: 2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo given in Part 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine given at a fixed dose level of 0.5 U/kg
Study: NCT03850860

Intervention type: OTHER
Intervention: empirical antibiotherapy
Description: comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies

Intervention type: OTHER
Intervention: empirical antibiotherapy
Description: comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
Study: NCT00700440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C225 (cetuximab)
Description: one week before and then weekly during radiotherapy
Study: NCT03087513

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
Study: NCT00720590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily dose of placebo for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily dose of placebo for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo for 4 weeks
Study: NCT00795704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mulberry Leaf Extract
Description: Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
Study: NCT01001559

Intervention type: DRUG
Intervention: L-methylfolate
Description: Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily

Intervention type: DRUG
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.

Intervention type: DRUG
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.

Intervention type: DRUG
Intervention: Serotonin and norepinephrine reuptake inhibitor (SNRI)
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.

Intervention type: DRUG
Intervention: Serotonin and norepinephrine reuptake inhibitor (SNRI)
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
Study: NCT00611429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling sessions
Description: The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling sessions
Description: The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group workshop
Description: During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group workshop
Description: During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
Study: NCT00795704

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 500 mg #2 capsules by mouth three times daily
Study: NCT00773162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seroquel
Description: seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Sugar pill to match seroquel
Study: NCT00286585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational anesthetic
Description: Sevoflurane, dosage according to the physician in charge

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous anesthetic, propofol
Description: Propofol, dosage according to the physician in charge
Study: NCT03469063

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AferBio
Description: Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: AferBio
Description: Patients will use the product (AferBio/Placebo) once a day for seven days, and then twice a day, continuously (for a total of three months of use).
Study: NCT00187863

Intervention type: BEHAVIORAL
Intervention: pain perception
Description: pain perception

Intervention type: BEHAVIORAL
Intervention: pain perception
Description: pain perception
Study: NCT01486966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human soluble insulin
Description: Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For subjects previously treated with metformin, the dosage and frequency will be kept unchanged

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
Study: NCT02532517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CODMAN ENTERPRISE® Vascular Reconstruction Device and Delivery System
Study: NCT00622037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG-400 based artificial tear
Description: Instill one drop in the randomized eye four times daily. Can be used more frequently if needed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane
Description: Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
Study: NCT02221869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xyrem
Study: NCT04965324

Intervention type: OTHER
Intervention: Anaesthesia Depth

Intervention type: OTHER
Intervention: Anaesthesia Depth
Study: NCT02354235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teneligliptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Teneligliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03189537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)
Description: Broad-spectrum antiviral agent

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule to match Ingavirin capsule
Study: NCT03522792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotensin
Description: Intravenous infusion of neurotensin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotensin
Description: Intravenous infusion of neurotensin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurotensin
Description: Intravenous infusion of neurotensin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intravenous infusion of saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum meal
Description: Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum meal
Description: Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum meal
Description: Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum meal
Description: Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ad libitum meal
Description: Participants will be served a large meal serving. They will be instructed to eat until they do not feel hungry anymore.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
Study: NCT01618604

Intervention type: PROCEDURE
Intervention: Quantitative Sensory Testing
Description: following the standardized protocol of DFNS

Intervention type: PROCEDURE
Intervention: Conditioned Pain Modulation
Description: test stimulus by hot thermode conditioned stimulus by cold water bath
Study: NCT03522792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid meal
Description: A standardized mixed liquid meal will be ingested to stimulate endogenous peptide hormone release
Study: NCT05887921

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Lymphadenectomy
Description: arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Lymphadenectomy
Description: arm A: open lymphadenectomy performed by a surgical team with extensive experience in traditional surgery arm B: laparoscopic lymphadenectomy performed by a surgical team with extensive experience in minimally invasive surgery
Study: NCT04049487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will participate in group exercise as previously described

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Both groups will participate in group exercise as previously described
Study: NCT01827150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Redbull, energy drink
Description: A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
Study: NCT02668497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study: NCT04044469

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immunization-enhancement
Description: This group receives a standardized information text, suggesting that medical diagnostics is not very accurate. Reasons for why a serious disease is overlooked are mentioned and discussed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immunization-inhibition
Description: This group receives a standardized information text, suggesting that medical diagnostics is very accurate and that doctors are very often right in their first initial diagnostic assessments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group
Description: This group receives no further information after watching the videotaped doctor's report.
Study: NCT04549545

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivaer ARC Stylus
Description: The Vivaer procedure will be performed in the study clinic using the Vivaer ARC Stylus and Aerin Console. The Vivaer ARC Stylus is a disposable handheld device capable of delivering bipolar radiofrequency energy to tissue when connected to the Aerin Console radiofrequency generating device. Participants in this study will undergo bilateral treatment of the nasal valves in a single study session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The sham control procedure will be performed in the study clinic using the Vivaer ARC Stylus while audible sounds that accurately simulate the Aerin Console's active treatment are produced even though RF energy is not being generated or delivered. All other aspects of the procedure will be the same as used for the active treatment, including administration of anesthetic agent(s).
Study: NCT01372059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RGRM
Description: RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic riding
Description: The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.

Intervention type: OTHER
Group type: OTHER
Intervention: Receives no intervention
Description: Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
Study: NCT01618604

Intervention type: PROCEDURE
Intervention: Repetition of four QST parameters
Description: * warm detection threshold (WDT)~* cold detection threshold (CDT)~* mechanical detection threshold (MDT)~* mechanical pain threshold (MPT)
Study: NCT01920854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: soluble ferric pyrophosphate
Study: NCT01260714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone Hydrochloride
Description: Given IV
Study: NCT03947710

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein meals
Description: Patients on maintenance hemodialysis will consume high protein meals during dialysis for one week (3 dialysis sessions)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low- protein meals
Description: Patients on maintenance hemodialysis will consume low protein meals during dialysis for one week (3 dialysis sessions)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No meals
Description: Patients on maintenance hemodialysis will not consume meals during dialysis for one week (3 dialysis sessions)
Study: NCT02928315

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
Study: NCT04683835

Intervention type: DEVICE
Intervention: Neurosteer Aurora system
Description: The system is composed of hardware and software modules that facilitate the capture and interpretation of electrophysiological data as well as enable viewing the processed data in real time and offline. An electrode patch is attached on the subject's forehead to capture the electrophysiological signal. The signal is sent via low energy Bluetooth to an EEG Monitor. The signal is then sent via Wi-Fi to the cloud where the data is stored on a HIPAA compliant server. Data analysis performed in the cloud transforms the electrophysiological signal into easily readable data of brain activity, which is accessible via any web interface